Antidote Technologies and SEQSTER Join Forces to Improve Patient Identification & Enrollment for Clinical Trials


Antidote and SEQSTER have collaborated to improve patient identification & recruitment as well as enhance trial timelines for healthcare firms
Antidote will combine its screening and support services and SEQSTER Operating System to identify patients for clinical studies after looking into their comprehensive medical history, genomic data & lifestyle factors, expediting enrollment for trials
The partnership between SEQSTER and Antidote streamlines patient enrollment, reducing trial startup time. Antidote’s personalized services and SEQSTER’s technology will further improve patient engagement & adherence to trial protocols and data accuracy

Ref: Antidote | Image: Antidote 

Related News:- Boehringer Ingelheim Collaborates with Walgreens to Improve Clinical Trials Access

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at